<DOC>
	<DOC>NCT01600079</DOC>
	<brief_summary>This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.</brief_summary>
	<brief_title>ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming ageeligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Varicella-zoster vaccine</keyword>
	<keyword>herpes zoster</keyword>
	<keyword>shingles</keyword>
	<keyword>Varicella-zoster virus</keyword>
	<keyword>postherpetic neuralgia</keyword>
	<keyword>Herpesviridae Infections</keyword>
	<keyword>DNA Virus Infections</keyword>
	<keyword>Virus Diseases</keyword>
</DOC>